- Home
- TLSA vs STRW Comparison
TLSA vs STRW Comparison
Compare TLSA & STRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | STRW |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.1M | 197.5M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TLSA | STRW |
|---|---|---|
| Price | $1.01 | $13.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.88 |
| AVG Volume (30 Days) | ★ 569.4K | 35.3K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 5.17% |
| EPS Growth | N/A | ★ 5.26 |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | ★ $154,999,000.00 |
| Revenue This Year | N/A | $8.52 |
| Revenue Next Year | N/A | $3.95 |
| P/E Ratio | ★ N/A | $40.21 |
| Revenue Growth | N/A | ★ 32.41 |
| 52 Week Low | $0.76 | $11.11 |
| 52 Week High | $2.33 | $14.75 |
Technical Indicators
Market Signals| Indicator | TLSA | STRW |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 41.29 |
| Support Level | $0.90 | $13.22 |
| Resistance Level | $1.20 | $14.07 |
| Average True Range (ATR) | 0.08 | 0.37 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 72.74 | 20.39 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.